{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "418"
        },
        "variant_string_id": "PARK2 C418R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin acts as a transcriptional repressor of p53 independently of its ubiquitin ligase function, and mutations associated with familial AR-JP abolish this control.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that the disease mechanism involves the loss of parkin's ability to repress p53 transcription, which is linked to apoptosis in dopaminergic neurons."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays to measure p53 expression, promoter transactivation, and caspase-3 activity, which are relevant to the disease mechanism of p53 dysregulation.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism of p53 dysregulation, which is relevant to Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type parkin and multiple replicates for experiments.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included, allowing for reliable interpretation of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants as controls, such as C441R, which also abolishes parkin's function.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, providing a benchmark for assessing the functional impact of the C418R variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but includes multiple pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses more than 11 pathogenic controls, allowing for a moderate strength of evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The C418R variant in the PARK2 gene shows a moderate strength of pathogenicity due to its significant impact on p53 transcriptional repression, validated by multiple pathogenic controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "441"
        },
        "variant_string_id": "PARK2 C441R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin acts as a transcriptional repressor of p53 independently of its ubiquitin ligase function, and mutations associated with familial AR-JP abolish this control.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that the disease mechanism involves the loss of parkin's ability to repress p53 transcription, which is linked to apoptosis in dopaminergic neurons."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays to measure p53 expression, promoter transactivation, and caspase-3 activity, which are relevant to the disease mechanism of p53 dysregulation.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism of p53 dysregulation, which is relevant to Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type parkin and multiple replicates for experiments.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included, allowing for reliable interpretation of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants as controls, such as C418R, which also abolishes parkin's function.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, providing a benchmark for assessing the functional impact of the C441R variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but includes multiple pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses more than 11 pathogenic controls, allowing for a moderate strength of evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The C441R variant in the PARK2 gene shows a moderate strength of pathogenicity due to its significant impact on p53 transcriptional repression, validated by multiple pathogenic controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "161"
        },
        "variant_string_id": "PARK2 K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin acts as a transcriptional repressor of p53 independently of its ubiquitin ligase function, and mutations associated with familial AR-JP abolish this control.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that the disease mechanism involves the loss of parkin's ability to repress p53 transcription, which is linked to apoptosis in dopaminergic neurons."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays to measure p53 expression, promoter transactivation, and caspase-3 activity, which are relevant to the disease mechanism of p53 dysregulation.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism of p53 dysregulation, which is relevant to Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type parkin and multiple replicates for experiments.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included, allowing for reliable interpretation of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants as controls, such as C418R, which also abolishes parkin's function.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, providing a benchmark for assessing the functional impact of the K161N variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but includes multiple pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses more than 11 pathogenic controls, allowing for a moderate strength of evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The K161N variant in the PARK2 gene shows a moderate strength of pathogenicity due to its significant impact on p53 transcriptional repression, validated by multiple pathogenic controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "256"
        },
        "variant_string_id": "PARK2 R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin acts as a transcriptional repressor of p53 independently of its ubiquitin ligase function, and mutations associated with familial AR-JP abolish this control.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that the disease mechanism involves the loss of parkin's ability to repress p53 transcription, which is linked to apoptosis in dopaminergic neurons."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays to measure p53 expression, promoter transactivation, and caspase-3 activity, which are relevant to the disease mechanism of p53 dysregulation.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism of p53 dysregulation, which is relevant to Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type parkin and multiple replicates for experiments.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included, allowing for reliable interpretation of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants as controls, such as C418R, which also abolishes parkin's function.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, providing a benchmark for assessing the functional impact of the R256C variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but includes multiple pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses more than 11 pathogenic controls, allowing for a moderate strength of evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R256C variant in the PARK2 gene shows a moderate strength of pathogenicity due to its significant impact on p53 transcriptional repression, validated by multiple pathogenic controls."
    }
  ]
}
